Chiusura precedente | 32,50 |
Aperto | 31,53 |
Denaro | 0,00 x 0 |
Lettera | 32,36 x 100 |
Min-Max giorno | 31,53 - 32,82 |
Intervallo di 52 settimane | 26,06 - 46,40 |
Volume | |
Media Volume | 13.488 |
Capitalizzazione | 277,74M |
Beta (5 anni mensile) | 1,63 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,52 |
Prossima data utili | 13 mag 2024 - 17 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 44,00 |
FORT WORTH, TX, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, wound and skincare markets, announced today the first sale of ALLOCYTE® Plus Advanced Viable Bone Matrix (“ALLOCYTE Plus” or “ALLOCYTE+”). ALLOCYTE Plus First Sale As previously disclosed
FORT WORTH, TX, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that Zach Fleming, the Company’s Chief Executive Officer, will present at the MicroCapClub Leadership Summit in Chicago, Illinois, on
FORT WORTH, TX, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter ended June 30, 2023. Z